Clinical Trials Browser

Phase 1/2 × Immunotherapy, Adoptive × 90 days × Clear all

NCT06768905 2026-04-16

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse